The Effect Of PF-03654764 +/- Allegra On Symptoms Of Allergic Rhinitis

Last updated: August 16, 2010
Sponsor: Pfizer
Overall Status: Completed

Phase

2

Condition

Rhinitis, Allergic, Perennial

Allergy

Common Cold

Treatment

N/A

Clinical Study ID

NCT01033396
B0711005
  • Ages 18-60
  • All Genders

Study Summary

PF-03654764 should reduce the symptoms of allergic rhinitis. In this study patients will be exposed to pollen and their symptoms observed.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Male or female subjects 18-60 years allergic to ragweed pollen.

  • Subjects with appropriate symptom scores following exposure to ragweed in theenvironmental exposure unit.

Exclusion

Exclusion Criteria:

  • Subjects with significant diseases other than allergic rhinitis that may interferewith the safety or efficacy of PF-03654764.

  • Subjects with significant symptoms of allergic rhinitis within the 2 weeks prior toscreening.

Study Design

Total Participants: 64
Study Start date:
January 01, 2010
Estimated Completion Date:
May 31, 2010

Connect with a study center

  • Pfizer Investigational Site

    Kingston, Ontario K7L 2V7
    Canada

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.